Abstracts tagged "Biologicals"

Abstract Number: 2467 • ACR Convergence 2025
Complete Renal Responses and Safety for Belimumab Versus Placebo in a Post Hoc Mycophenolate Mofetil Subgroup with Active Proliferative Lupus Nephritis
Richard Furie¹, Hans-Joachim Anders², George Bertsias³, Ana Delgado⁴, Roger A. Levy⁵, Paula Curtis⁶, Ciara O'Shea⁷, Ryan Tomlinson⁸ and Brad Rovin⁹, ¹Division of Rheumatology, Northwell Health, Great Neck, NY, ²Hospital of LMU Munich, Department of Medicine IV, Munich, Germany, ³Rheumatology and Clinical Immunology, University Hospital of Heraklion and University of Crete Medical School and Foundation for Research and Technology-Hellas (FORTH), Infections and Immunity, Institute of Molecular Biology and Biotechnology, Heraklion, Greece, ⁴GSK, Immunology Medical Affairs, London, United Kingdom, ⁵GSK, Specialty Care, Global Medical Affairs, Collegeville, PA, ⁶GSK, Biostatistics, London, United Kingdom, ⁷Global Medical Affairs, GSK, Dublin, Ireland, ⁸GSK, Development – R&D, Collegeville, PA, ⁹The Ohio State University, Columbus, OH
Background/Purpose: Belimumab, a human IgG1λ monoclonal antibody that selectively binds B-lymphocyte stimulator, was first approved in 2011. It is the only biologic approved for LN…
Abstract Number: 2346 • ACR Convergence 2025
Back in Action: Six Months of Biological Therapy Improve Sexual Function in Men with Ankylosing Spondylitis
Daniel Zavada¹, Barbora Vala², Adela Navratilova², Veronika Losterova², Lenka Moravcova², Jiri Vencovsky³, Ladislav Šenolt⁴, Karel Pavelka⁵ and Michal Tomcik⁵, ¹Institute of Rheumatology, Prague; Charles University, Third Faculty of Medicine, Hlavné mesto Praha, Czech Republic, ²Institute of Rheumatology, Praha, Czech Republic, ³Institute of Rheumatology, Praha ⁸, Czech Republic, ⁴Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁵Institute of Rheumatology and Department of Rheumatology, ¹st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: Ankylosing spondylitis (AS) significantly impacts quality of life across multiple domains. To date, no studies have evaluated the impact of initial biological therapy on…
Abstract Number: 2041 • ACR Convergence 2025
Evaluating Biologic Effectiveness in Co-Occurring Dermatologic and Rheumatic Disease: A Systematic Review
Nashwah Memon¹, Dylan Wambold², Omar Alani³, Syed Minhaj Rahman⁴ and Adel Haque⁵, ¹Lake Erie College of Osteopathic Medicine, Miami, ²Drexel University College of Medicine, Philadelphia, ³Icahn School of Medicine at Mount Sinai, New York, ⁴Department of Medicine, Northwell Health Northern Westchester Hospital, Mount Kisco, ⁵Jefferson Health Northeast, Philadelphia
Background/Purpose: Clinicians prescribing biologics must be aware of the expanding indications for biologic/systemic therapies across dermatology and rheumatology alike. Given disease-state overlap between these fields,…
Abstract Number: 1605 • ACR Convergence 2025
Combined Anti-IL-5/IL-5R and Dupilumab Therapy in Eosinophilic Granulomatosis with Polyangiitis: A European Retrospective Study
Miriam Guerini¹, Pavel Novikov², Roberto Padoan³, Georgina Espigol-Frigole⁴, Jan Willem Cohen Tervaert⁵, Vincent Grobost⁶, Laurent Guilleminault⁷, Jan Walter Schroeder⁸, Bernhard Hellmich⁹, Joana Martins-Martinho¹⁰, Camillo Ribi¹¹, Mathieu Groh¹² and Benjamin Terrier¹³, ¹IRCCS Policlinico S. Matteo, University of Pavia, Pavia, Italy, ²Sechenov University, Moscow, Russia, ³University of Padova, Padova, Italy, ⁴Hospital Clínic de Barcelona, Barcelona, Spain, ⁵University of Alberta, Edmonton, AB, Canada, ⁶Internal medicine, CHU Clermont Ferrand Estaing, Clermont Ferrand, France, ⁷CHU Toulouse, Toulouse University, Toulouse, France, ⁸ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy, ⁹Klinik für Innere Medizin, Rheumatologie und Immunologie, medius Klinik Kirchheim, Kirchheim unter Teck, Germany, ¹⁰ULS Santa Maria, Lisbon, Portugal, ¹¹Lausanne University Hospital / University of Lausanne, Lausanne, Switzerland, ¹²Hôpital Foch, Suresnes, France, ¹³Cochin Hospital, Paris, France
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a small-vessel vasculitis characterized by asthma, ear, nose, and throat (ENT) symptoms, eosinophilia, and systemic involvement. Despite the…
Abstract Number: 1460 • ACR Convergence 2025
Effect of Guselkumab and IL-17 Inhibitors on Work Productivity and Activity Impairment in Psoriatic Arthritis: 6-Month Results of the PsABIOnd Observational Study
Stefan Siebert¹, Mohamed Sharaf², Frank Behrens³, Proton Rahman⁴, mitsumasa kishimoto⁵, Enrique R. Soriano⁶, Emmanouil Rampakakis⁷, László Köleséri⁸, Karissa Lozenski⁹, Ruben Queiro¹⁰, Ennio Lubrano¹¹ and Laure Gossec¹², ¹University of Glasgow, Glasgow, United Kingdom, ²Janssen - Johnson & Johnson, Dubai, United Arab Emirates, ³Goethe-University & Fraunhofer ITMP, Frankfurt, Germany, ⁴Division of Rheumatology, Craig L. Dobbin Genetics Research Centre, Discipline of Medicine, Memorial University of Newfoundland, St. John's, Canada, ⁵Kyorin University School of Medicine, Tokyo, Japan, ⁶Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires and University Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁷JSS Medical Research, Montréal, QC, Canada, ⁸IQVIA, Budapest, Hungary, ⁹Johnson & Johnson, Horsham, PA, ¹⁰Hospital Universitario Central de Asturias, Oviedo. Asturias, Spain, ¹¹Department of Medicine, Università deglia Studi del Molise, CAMPOBASSO, Italy, ¹²Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France
Background/Purpose: Work impairment is a key issue in PsA. Biologic treatments can improve work status in patients (pts) with PsA; however, there is lack of…
Abstract Number: 1356 • ACR Convergence 2025
Use of (MSB11456), the first tocilizumab biosimilar approved for rheumatoid arthritis: 6-month data from an international observational study
Jonathan Kay¹, Eugen feist², Ernest Choy³, Joerg Kaufmann⁴, Ernest Wong⁵, Hector Corominas⁶, René-Marc Flipo⁷, Jérôme Avouac⁸, María América López Lasanta⁹, Joelle Monnet¹⁰, Peter Baker¹¹, Maria Romanova Michailidi¹², Fabrizio Dolfi¹¹ and Graziella Pourcel¹³, ¹UMass Chan Medical School, Worcester, MA, ²Helios Department of Rheumatology, Vogelsang-Gommern, Germany, ³Division of Infection and Immunity, CREATE Centre, Cardiff University, Cardiff, United Kingdom, ⁴NA, Ludwigsfelde, Germany, ⁵Portsmouth Hospitals University NHS Trust, Portsmouth, United Kingdom, ⁶Hospital de Sant Pau, Barcelona, Spain, ⁷Université de Lille, CHU Lille, Service de rhumatologie, Lille, France, Lille, France, ⁸Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France, ⁹Hospital Universitario Vall d´Hebron, Barcelona, Spain, ¹⁰Fresenius Kabi SwissBioSim, Eysins, Switzerland, ¹¹Fresenius Kabi Biopharma, Eysins, Switzerland, ¹²University of Geneva, Eysins, Switzerland, ¹³Fresenius Kabi Biopharma, Eyzins, France
Background/Purpose: Although most healthcare professionals are convinced of the quality, safety, and favorable economic impact of biosimilars, their routine use is not yet widespread. MSB11456…
Abstract Number: 1122 • ACR Convergence 2025
A Retrospective Study of Adverse Cardiovascular Events in Patients Started on JAK Inhibitors at Two Major Health Systems in Northeast Ohio: Analysis of the 2019 JAK Inhibitors FDA Boxed Warning for Increased Risk of Serious Heart-Related Problems
William Koch¹, Donald Anthony², Janeen Leon² and Nora G. Singer², ¹University Hospitals Parma Medical Center, Parma, OH, ²The MetroHealth System at Case Western Reserve University School of Medicine, Cleveland, OH
Background/Purpose: Janus kinase (JAK) inhibitors are immunosuppressive medications that target the JAK-STAT signaling pathway. Tofacitinib (Xeljanz) was the first JAK inhibitor approved for the treatment…
Abstract Number: 0659 • ACR Convergence 2025
Human papillomavirus infection and systemic lupus erythematosus under biologic therapy: a retrospective analysis in a multicenter cohort
Ivette Casafont-Solé¹, Judit Font-Urgelles¹, Iñigo Rúa-Figueroa², Andrea Hernández-martín³, Tarek Salman Montes⁴, Marta De la Rubia Navarro⁵, Maria Piqueras García⁶, Sandra Garrote Corral⁷, EVA GLORIA TOMERO MURIEL⁸, Elena De la Mata Pinilla⁹, Belén Álvarez Rodríguez¹⁰, Julia Martínez Barrio¹¹, José Gomez-Puerta¹², Paola Vidal-Montal¹³, Eleonora Penzo¹⁴, Consuelo Ramos Giraldez¹⁵, Francisco Javier Novoa¹⁶, Vicenç Torrente-Segarra¹⁷, Jorge Juan Fragío Gil¹⁸, Leyre Riancho¹⁹ and Irene Altabás-González²⁰, ¹Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ²Hospital de Gran Canaria Doctor Negrin, Las Palmas GC, Spain, ³Hospital Universitario de Gran Canaria Dr Negrín, Las palmas, Spain, ⁴Hospital del Mar/Parc de Salut Mar-IMIM, Barcelona, Spain, ⁵Hospital de La Fe, Valencia, ⁶Servicio Murciano de Salud, Murcia, Spain, ⁷Hospital Ramón y Cajal, Madrid, ⁸Hospital Universitario de la Princesa, Madrid, Spain, ⁹Hospital ¹² de Octubre, Madrid, ¹⁰Hospital de Áraba, áraba, Spain, ¹¹Department of Rheumatology, Hospital Gregorio Marañón, Madrid, Spain, Madrid, Madrid, Spain, ¹²Rheumatology Department, Hospital Clinic, Barcelona, Spain, Barcelona, Spain, ¹³Rheumatology. Hospital Universitari de Bellvitge, Barcelona, Catalonia, Spain, ¹⁴Hospital Vall d'Hebrón, Barcelona, Spain, ¹⁵Hospital Universitario Virgen de Valme, Servicio de Reumatología, Seville, Spain, ¹⁶Hospital Insular de Gran Canaria, Las palmas, ¹⁷Hospital Comarcal Alt Penedés Garraf, Vilafranca del Penedès, Spain, ¹⁸Hospital General Universitario, Valencia, Spain, ¹⁹Hospital de Sierrallana, Torrelavega, ²⁰Complejo Hospitalario de Vigo, Vigo, Spain
Background/Purpose: Human papillomavirus (HPV) is responsible for 99.7% of cervical neoplasms and is the fourth most common cancer among women worldwide. Patients with systemic lupus…
Abstract Number: 0814 • ACR Convergence 2025
Pain Patterns in a Multicenter Randomized Trial of Early RA – Link Between Initially Sustained Joint Inflammation and Subsequent Non-inflammatory Pain Outcomes
Annie Brink¹, Johan Karlsson Wallman², Jon T Einarsson¹, Meliha Kapetanovic¹, Elisabeth Mogard¹, Elisabet Lindqvist¹, Carmen Roseman¹, Kristina Lend³, Merete Hetland⁴, Mikkel Ostergaard⁵, Kim Horslev-Petersen⁶, Dan Nordstrom⁷, Tuulikki Sokka-isler⁸, Bjorn Gudbjornsson⁹, Gerður María Gröndal⁹, Marte Heiberg¹⁰, Espen Haavardsholm¹⁰, Michael Nurmohamed¹¹, Anna Rudin¹², Ronald van Vollenhoven¹³, Till Uhlig¹⁰, Jon Lampa¹⁴ and Tor Olofsson², ¹Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Rheumatology, Lund, Sweden, ²Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Rheumatology, Lund, Skane Lan, Sweden, ³Department of Rheumatology and Amsterdam Rheumatology Center, Amsterdam University Medical Centers, Amsterdam; Department of Medicine, Rheumatology Unit, Center for Molecular Medicine (CMM), Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden, ⁴Copenhagen Center for Arthritis Research (COPECARE) and DANBIO, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup; Department of Clinical Medicine, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark, ⁵Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark, and Copenhagen Center for Arthritis Research, Center for Rheumatology, Rigshospitalet, Glostrup, Denmark, ⁶Danish Hospital for Rheumatic Diseases, University Hospital of Southern Denmark, Sønderborg; Department of Regional Health Research, University of Southern Denmark, Odense, Denmark, ⁷Division of Rheumatology, Helsinki University Hospital, Helsinki, Finland, ⁸Department of Medicine and University of Eastern Finland, Jyväskylä Central Hospital, Juväskylä, Finland, ⁹Landspitali University Hospital; Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ¹⁰Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ¹¹Amsterdam Rheumatology and Immunology Center, Reade; Department of Rheumatology and Amsterdam Rheumatology Center, Amsterdam University Medical Centers, Amsterdam, Netherlands, ¹²Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy of University of Gothenburg, Gothenburg, Sweden, ¹³Department of Rheumatology, Amsterdam University Medical Centre, Amsterdam, Netherlands, ¹⁴Department of Medicine, Rheumatology Unit, Center for Molecular Medicine (CMM), Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Emerging data indicate an uncoupling between pain and inflammation during the RA disease course, and comorbid fibromyalgia – thought to stem from central pain…
Abstract Number: 0487 • ACR Convergence 2025
Efficacy of sarilumab in patients with rheumatoid arthritis of different disease activity at treatment initiation: a post-hoc analysis of a Phase 3 trial of sarilumab in Japan
Hideto Kameda¹, Toshiya Takahashi², Naoki Soeda² and Yoshiya Tanaka³, ¹Department of Internal Medicine, Toho University, Tokyo, Japan, ²Medical Affairs, Asahi Kasei Pharma Corporation, Tokyo, Japan, ³University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
Background/Purpose: The efficacy and safety of sarilumab (SAR) and methotrexate (MTX) in patients (pts) in Japan with moderate-to-severely active rheumatoid arthritis (RA) and inadequate response…
Abstract Number: 0200 • ACR Convergence 2025
Severe infections and malignancies in patients with cranial and extracranial giant cell arteritis treated with tocilizumab. National multicenter study of 471 patients of clinical practice
Adrian Martin-Gutierrez¹, Javier Loricera², Vicente Aldasoro Cáceres³, Olga Maiz⁴, Eugenio de Miguel⁵, Eva Galíndez Agirregoikoa⁶, Ivan Ferraz Amaro⁷, Santos Castañeda⁸ and Ricardo Blanco⁹, ¹Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Renedo de Piélagos, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ³Hospital Universitario de Navarra, Pamplona, Spain, ⁴Hospital Universitario de Donosti, Donostia, Spain, ⁵Hospital Universitario La Paz, Madrid, Spain, ⁶BASURTO UNIVERSITY HOSPITAL, BILBAO, Spain, ⁷Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁸Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ⁹Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: Infections and malignancies are two of the most feared side effects of biologic therapies. Giant cell arteritis (GCA) is a vasculitis which affects older…
Abstract Number: 2689 • ACR Convergence 2025
Comparison of Incidence of Psoriatic Arthritis in Patients With Psoriasis Treated With Interleukin-17 Inhibitors vs Interleukin-23 Inhibitors, Interleukin-12/23 Inhibitors, and Tumor Necrosis Factor Inhibitors in Real-World Practice: A Retrospective Study
April Armstrong¹, Joseph Merola², Gang Wang³, Ariane Faucher⁴, Riley Taiji⁴, Francis Vekeman⁴, Alexis Shew⁵, Tim Nguyen⁵ and Laura Coates⁶, ¹University of California Los Angeles, Los Angeles, CA, USA, Los Angeles, CA, ²UT Southwestern Medical Center, Dallas, TX, ³Department of Dermatology, Xijing Hospital, The Fourth Military Medical University, Xi'an, China (People's Republic), ⁴STATLOG, Inc, Montreal, QC, Canada, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom
Background/Purpose: Biologic therapies for moderate to severe psoriasis (PsO) include inhibitors of IL-17 (IL-17i), IL-23i, IL-12/23i, and tumor necrosis factor (TNFi). Previous studies that assessed…
Abstract Number: 2464 • ACR Convergence 2025
IMC-002 (IMM0306), a First-in-Class Bi-specific Fusion Protein, Demonstrates Improvements in Systemic Lupus Erythematosus (SLE) Disease Activity Measures and Biomarkers in Patients with Moderate to Severe Active SLE in the Open-label Phase 1b/2 Study
Haihong Yao¹, Wenzhi Tian², Qian Zheng², Min Chen², Guoping Jiang³, Zhichun Liu⁴, Yingkun Nie⁵, Rui Wu⁶, Zhaohui Zheng⁷ and Zhanguo Li¹, ¹Peking University People's Hospital, Beijing, China (People's Republic), ²ImmuneCare Biopharmaceuticals (Shanghai) Co.,Ltd, Shanghai, China (People's Republic), ³Jilin Province People's Hospital, Changchun, China (People's Republic), ⁴The Second Affiliated Hospital of Soochow, Suzhou, China (People's Republic), ⁵The Second Affiliated Hospital of Harbin Medical University, Haerbin, China (People's Republic), ⁶The First Affiliated Hospital of Nanchang University, Nanchang, China (People's Republic), ⁷The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China (People's Republic)
Background/Purpose: Deep B cell depletion has been confirmed to be the main mechanism for complete clinical response of SLE patients. We analyzed the peripheral blood…
Abstract Number: 2344 • ACR Convergence 2025
Impact of Bimekizumab Use in Spondyloarthritis and Psoriatic Arthritis: Persistence Study in Routine Clinical Practice in Spain (BIMPACT study)
Cristina Valero¹, Chamaida Plasencia-Rodríguez², Maria Beatriz Paredes Romero³, Silvia Montes⁴, Josefina Marin⁵, Aranzazu Rubio⁶, Cristina Macía-Villa⁷, Laura Gonzalez Hombrado⁸, Maria Luisa Gonzalez Gomez⁹, Maria Carmen Ortega de la O¹⁰, Mercedes Morcillo Valle¹¹, Rosario Garcia Vicuña¹², EVA GLORIA TOMERO MURIEL¹², Diana Peiteado² and BEATRIZ JOVEN¹³, ¹Hospital de la Princesa, Madrid, Spain, ²Hospital Universitario La Paz, MADRID, Spain, ³Infanta Sofía University Hospital, Madrid, Spain, ⁴Hospital de Talavera, Talavera, Castilla-La Mancha, Spain, ⁵Hospital Universitario Rey Juan Carlos, Madrid, Spain, ⁶Hospital Universitario Infanta Cristina, Madrid, Spain, ⁷Hospital Universitario Ramon y Cajal, Madrid, Spain, ⁸Hospital Universitario del Tajo, Aranjuez (MADRID), Madrid, Spain, ⁹Hospital Universitario El Escorial, Majadahonda, Spain, ¹⁰Hospital Universitario Getafe, Madrid, Madrid, Spain, ¹¹Hospital El Escorial, San Lorenzo de El Es, Spain, ¹²Hospital Universitario de la Princesa, Madrid, Spain, ¹³H. Universitario ¹² Octubre, Madrid, Spain
Background/Purpose: Bimekizumab (BKZ) is a monoclonal antibody that simultaneously blocks IL-17A, IL-17F, and their heterodimer, key cytokines involved in the pathogenesis of spondyloarthritis (SpA) and…
Abstract Number: 2038 • ACR Convergence 2025
Real-World Use of Dual Targeted Therapy in Rheumatic Disease: A Single-Center Case Series
Marta Aguilar Zamora¹, Karla Romelia Arévalo Ruales², marta Garijo Bufort², Maria Isabel Pastor Orduña¹, Celia Aparicio Rubio³, Silvia Cornejo Uixeda⁴ and Joaquín Borrás Blasco⁴, ¹Rheumatology Department, Hospital de Sagunto, Spain, Puerto de Sagunto, Comunidad Valenciana, Spain, ²Rheumatology Department, Hospital de Sagunto, Spain, valencia, Spain, ³Pharmacy Department, Hospital de Sagunto, Spain, Puerto de Sagunto, ⁴Pharmacy Department, Hospital de Sagunto, Spain, Puerto de Sagunto, Spain
Background/Purpose: Combination therapy with two biologic agents (bDMARDs) or a biologic plus a Janus kinase inhibitor (JAKi) is rarely used in rheumatology due to safety…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].